Pharmacokinetics of metformin
Pro Research Analysisby 
Searched over 200M research papers
Metformin Pharmacokinetics: Absorption, Distribution, and Elimination
Metformin is widely used as a first-line treatment for type 2 diabetes and is characterized by high pharmacokinetic variability among individuals. After oral administration, metformin is absorbed in the intestine, distributed throughout the body, and primarily eliminated unchanged by the kidneys. Its pharmacokinetics are often described using two-compartment models, though some studies use a one-compartment approach Wang2022Zake2021. The drug exists as a hydrophilic cation at physiological pH, so its movement across cell membranes relies heavily on specific transporters Markowicz-Piasecka2017Froldi2024Liang2017.
Role of Transporters in Metformin Pharmacokinetics
Transporters such as Organic Cation Transporters (OCTs) and Multidrug and Toxin Extrusion (MATE) proteins are crucial for metformin’s absorption, tissue distribution, and renal elimination. These transporters mediate metformin’s entry into target tissues and its excretion via the kidneys Markowicz-Piasecka2017Froldi2024Burt2016+1 MORE. Genetic variations in these transporters can significantly affect metformin’s pharmacokinetics and therapeutic response Wang2022Markowicz-Piasecka2017Liang2017. For example, inhibition of OCTs and MATEs by other drugs, such as cimetidine, can increase metformin plasma concentrations by reducing its renal clearance .
Factors Influencing Metformin Pharmacokinetics
Several factors contribute to the variability in metformin pharmacokinetics:
- Renal Function: Metformin is eliminated mainly through the kidneys, so creatinine clearance and the degree of renal impairment significantly impact its clearance and dosing requirements Wang2022Markowicz-Piasecka2017Froldi2024.
- Body Weight and Species Differences: Allometric scaling shows that systemic clearance of metformin correlates with body weight across species, but tissue distribution varies widely, likely due to differences in transporter expression Jeong2021Zake2021.
- Obesity and Pathological Conditions: Obesity and other pathological states can alter metformin’s pharmacokinetic parameters, necessitating individualized dosing .
- Time-of-Day and Chronotype: Metformin pharmacokinetics are influenced by the time of day, with daily rhythms in renal and hepatic processes affecting drug levels. Individual chronotypes also contribute to interindividual variability in metformin concentrations and efficacy .
- Gut Microbiota: The gut microbiota can modulate metformin’s pharmacokinetics and pharmacodynamics, partly by affecting the expression of hepatic transporters like OCT1 .
Tissue Distribution and First-Pass Effects
Metformin’s distribution is dominated by tissues such as muscle, with low permeability and partitioning, but actual tissue concentrations are influenced by transporter-mediated uptake, especially in the liver, kidney, and gastrointestinal tract Jeong2021Zake2021. The highest concentrations are found in the intestine (site of absorption) and kidney (site of excretion), followed by the liver . A significant first-pass pharmacodynamic effect occurs in the liver and gut wall, contributing to metformin’s glucose-lowering action beyond what is explained by plasma concentrations alone .
Implications for Individualized Therapy
Given the high variability in metformin pharmacokinetics due to genetic, physiological, and environmental factors, individualized dosing regimens are important for optimizing efficacy and minimizing side effects Wang2022Markowicz-Piasecka2017Zake2021+1 MORE. Physiologically based pharmacokinetic (PBPK) models can help simulate metformin concentrations in various tissues and support precision therapy development .
Conclusion
Metformin’s pharmacokinetics are complex and influenced by multiple factors, including transporter activity, renal function, body weight, time-of-day, and gut microbiota. Understanding these factors is essential for optimizing metformin therapy and developing personalized treatment strategies for patients with type 2 diabetes and other conditions.
Sources and full results
Most relevant research papers on this topic
Research Progress of Population Pharmacokinetic of Metformin
Metformin pharmacokinetics are influenced by obesity, creatinine clearance, gene polymorphism, renal function damage, and pathological conditions, emphasizing the need for individualized dosing regimens.
Meta-Assessment of Metformin Absorption and Disposition Pharmacokinetics in Nine Species
Metformin absorption and renal clearance are highly correlated with body weight, but tissue distribution varies significantly due to transporter differences.
Is Metformin a Perfect Drug? Updates in Pharmacokinetics and Pharmacodynamics.
Metformin's pharmacokinetics and pharmacodynamics have improved, with new insights into its effects on lipid profile, cardiovascular system, and oncology, and new synthetic derivatives and pro-drugs.
Physiologically based metformin pharmacokinetics model of mice and scale-up to humans for the estimation of concentrations in various tissues
The developed PBPK model for metformin in humans can estimate concentrations in various tissues, aiding in precision therapy development for individual patients.
Significant impact of time-of-day variation on metformin pharmacokinetics
Metformin pharmacokinetics significantly depends on time-of-day in humans, with rhythmic GFR, RPF, and OCT2 governing intraday variation, and interindividual variation partly dependent on individual chronotype.
Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions.
Cimetidine's inhibition of OCT and MATE transporters in metformin kinetics can be accurately simulated using physiologically-based pharmacokinetic models, but requires incorporating complex electrochemical interactions and cimetidine concentrations.
DOI